4-chloro-2-(4-methanesulfonylphenyl)-6-trifluoromethylpyrimidine | 1018481-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-2-(4-methanesulfonylphenyl)-6-trifluoromethylpyrimidine
• CAS: 1018481-30-5
• 化学式: C₁₂H₈ClF₃N₂O₂S
• 分子量: 336.722
• InChiKey: RJHUIRCMUGTUOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.22
• 重原子数：
  21.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.92
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (1H-苯并咪唑-2-亚甲基)胺 、 4-chloro-2-(4-methanesulfonylphenyl)-6-trifluoromethylpyrimidine 在 三乙胺 作用下， 以95%的产率得到N-(1H-benzimidazol-2-ylmethyl)-2-(4-methylsulfonylphenyl)-6-(trifluoromethyl)pyrimidin-4-amine
  参考文献：
  名称：

  Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors

  摘要：

  New series of 2-(4-methylsulfonylphenyl) and 2-(4-sulfamoylphenyl)pyrimidines were synthesized and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). COX-1 and COX-2 inhibitory activity of these compounds was determined using purified enzyme (PE) and human whole blood (HWB) assays. Extensive structure-activity relationship (SAR) work was carried out within these series, and a wide number of potent and specific COX-2 inhibitors were identified (HWB COX-2 IC50 = 2.4-0.3 nM and 80- to 780-fold more selective than rofecoxib). (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.079
• 作为产物：
  描述：

  4-chloro-2-(4-methylsulfanylphenyl)-6-trifluoromethylpyrimidine 在 Oxone 作用下， 以 四氢呋喃 、 水 为溶剂， 以93%的产率得到4-chloro-2-(4-methanesulfonylphenyl)-6-trifluoromethylpyrimidine
  参考文献：
  名称：

  Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors

  摘要：

  New series of 2-(4-methylsulfonylphenyl) and 2-(4-sulfamoylphenyl)pyrimidines were synthesized and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). COX-1 and COX-2 inhibitory activity of these compounds was determined using purified enzyme (PE) and human whole blood (HWB) assays. Extensive structure-activity relationship (SAR) work was carried out within these series, and a wide number of potent and specific COX-2 inhibitors were identified (HWB COX-2 IC50 = 2.4-0.3 nM and 80- to 780-fold more selective than rofecoxib). (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.079